In his editorial, Dr. Clifford Hudis writes: "This multigene assay is unlikely to be the only test that can provide a prediction of chemotherapy benefit. A less expensive and broadly distributed test would be valuable globally. For now, however, this assay is the most rigorously tested option and provides proof of the principle that we can develop reproducible predictive tests to select patients who should not receive chemotherapy. In that regard, it is one more step toward precision. There are more steps ahead."
Over the past 8 days, we've discussed some of these potential 'next steps ahead' including gaining more clarity within the RS 11-17 group - this may arise following the completion of the TAILORx trial.
In your view, what are some even further 'next steps' toward predictive precision?